Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Improved Antidepressant Remission in Major Depression via a Pharmacokinetic Pathway Polygene Pharmacogenetic Report

5 Aug 2015

Abstract excerpt

OBJECTIVE: Major depressive disorder (MDD) is projected to be a leading cause of disability globally by 2030. Only a minority of patients remit with antidepressants. If assay of polymorphisms influencing central nervous system (CNS) bioavailability could guide prescribers to more effectively dose patients, remission rates may improve and the burden of disease from MDD reduce. Hepatic and blood brain barrier (BBB)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Neurotransmitter Receptor Influence on Behavior
Share to Pharmacogenetics and Drug Metabolism
Share to Treatment of Major Depression

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26243841
DOI: 10.9758/cpn.2015.13.2.150

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Improved Antidepressant Remission in Major Depression via a Pharmacokinetic Pathway Polygene Pharmacogenetic ReportPMID 26243841Read ↗

Antidepressant pharmacogeneticsSemantic proximity Read ↗

Pharmacogenomics for stratified antidepressant treatment in major depressive disorder: evidence, limits and a roadmap for clinical use.Semantic proximity Read ↗

Pharmacogenetic studies: a tool to improve antidepressant therapy.Semantic proximity Read ↗

Genetics of Treatment Outcomes in Major Depressive Disorder: Present and FutureSemantic proximity Read ↗

Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications.Semantic proximity Read ↗

Therapy response prediction in major depressive disorder: current and novel genomic markers influencing pharmacokinetics and pharmacodynamics.Semantic proximity Read ↗

Genotype-Guided Antidepressant Prescribing for Patients With Depression: A Randomized Clinical Trial.Semantic proximity Read ↗

Pharmacogenomics of antidepressant drugs.Semantic proximity Read ↗

Clinical application of antidepressant pharmacogenetics: Considerations for the design of future studiesSemantic proximity Read ↗

Pharmacogenetics of antidepressant drugs: current clinical practice and future directions.Semantic proximity Read ↗

Sociodemographic, clinical, and genetic factors associated with self-reported antidepressant response outcomes in the UK Biobank.Semantic proximity Read ↗

From Pharmacogenetics to Pharmacogenomics: The Way toward the Personalization of Antidepressant TreatmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.